- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
BMY dropped after the bad news about a recent failed clinical trial of a new drug. But now the signs are there for a bullish reversal.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.